Pyrazolopyrimidines and related heterocycles as CK2 inhibitors

A compound of Formula (II):

• or a pharmaceutically acceptable salt or solvate thereof;
• wherein:
• Z3 is N;
• and Z4 is CR5 or CH;
• R5 is selected from halo, —CN, —R, —OR, —S(O)nR, —COOR, —CONR2, and —NR2,
• wherein each R is independently selected from H and optionally substituted C1-C4 alkyl, or alternatively, the two R groups, taken together with the nitrogen atom to which they are attached, form an optionally substituted 5 or 6 membered heterocyclic ring that optionally contains one or more additional heteroatom selected from N, O and S as a ring member;
• R2, R3 and R4 are each independently selected from H and optionally substituted C1-C10 alkyl;
• X represents O, S, or NR2;
• Y is O or S or NR10;
• where R10 is selected from H, CN, optionally substituted C1-C4 alkyl, optionally substituted C2-C4 alkenyl, optionally substituted C2-C4 alkynyl, optionally substituted C1-C4 alkoxy, and —NR7R8,
• Z is O or S;
• L is a bond, —CR7═CR8—, —C≡C—, —NR7—, —O—, —S(O)n—, —(CR7R8)m—, —(CR7R8)m—NR7—, —(CR7R8)m—O—, or —(CR7R8)m—S(O)n—;
• W is optionally substituted C1-C10 alkyl, optionally substituted C1-C10 heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, —NR7R8, —OR7, —S(O)nR7, —CONR7R8, optionally substituted heterocyclyl, optionally substituted carbocyclyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, or —CR7R8R9;
• where each R7 and R8 and R9 is independently selected from H, optionally substituted C1-C10 alkyl, optionally substituted heteroalkyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl;
• or R8 and R9 , taken together with the carbon atom to which they are attached, form ═O (oxo) or ═N—OR7 or ═N—CN;
• or R7 and R8, taken together on a single carbon atom or on adjacent connected carbon atoms of (CR7R8)m whether alone or as part of another group, form a 3 to 8 membered carbocyclic ring or heterocyclic ring;
• or R7 and R8, taken together with the nitrogen atom to which they are attached, form an optionally substituted 5 to 10 membered heterocyclic or heteroaryl ring that optionally contains one or more additional heteroatom selected from N, O and S as a ring member;
• provided that no more than one of or R7 and R8 in —NR7R8 is selected from the group consisting of alkoxy, alkylamino, dialkylamino and heterocyclyl;
• each n is independently is 0, 1 or 2;
• each m is independently 1, 2, 3 or 4;
• and
• R1A and R1B are each independently selected from H, optionally substituted C1-C10 alkyl, optionally substituted heteroalkyl, optionally substituted heterocyclyl, optionally substituted carbocyclyl, optionally substituted carbocyclylalkyl, optionally substituted heterocyclylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl;
• or R1A and R1B, taken together with the nitrogen atom to which they are attached, form an optionally substituted 5- to 8-membered monocyclic or 5- to 10-membered bicyclic heteroaryl or heterocyclic ring containing up to two additional heteroatoms selected from N, O and S as ring members.